Wilson Sonsini’s 3rd Annual Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI trends in healthcare, and developments in M&A. This unique event will bring together leaders from across the biotech industry, including esteemed researchers, policymakers, prominent investors, and CEOs.
Wednesday, October 21
6:00 – 9:00 p.m. Opening Reception and Dinner
Thursday, October 22
7:30 – 9:00 a.m. Registration and Networking Breakfast
8:00 a.m. – 5:00 p.m. Partnering Hall
9:00 a.m. – 6:20 p.m. Programming
6:20 – 8:30 p.m. Closing Reception
Accommodations:
We have contracted guest rooms at discounted pricing at The Newbury Boston. Your conference preferential hotel room rate is $549 and is guaranteed on a first come, first served basis until Thursday, September 17, 2026.
For room reservations, call The Newbury Boston at (617) 536-5700 and reference the “Wilson Sonsini Biotech Summit 2026” or click here for an online reservation.
Partnering Hall
Connect with innovative Biotech start-ups from around the globe through the Partnering Hall, which provides personalized opportunities for investors and large Pharma companies to meet with start-ups that are searching for and pursuing potential investment, partnering, and acquisition opportunities.
Biotech Summit 2025 Recap
Wilson Sonsini’s 2025 Biotech Summit attracted over 375 participants and featured a single-track program with 10 insightful sessions. Over 40 industry leaders participated as panelists and speakers in these sessions, addressing key topics such as venture capital and financing trends, patent strategies, and insights into the global pharmaceutical and life sciences industries.
Biotech 2024 Recap
Wilson Sonsini’s inaugural Biotech Summit convened diverse and influential leaders from across the biotech industry, including esteemed researchers, policymakers, prominent investors, and CEOs. The Biotech Summit, attended by over 250 participants, was structured around a single-track program comprising of 10 insightful sessions. More than 30 industry leaders contributed to these sessions as panelists and speakers, leading key industry topics including venture capital trends, antitrust issues, and FDA insights.